Syncona is continuing to bet big on gene therapy. While setbacks at other biotechs have taken the sheen off the modality, the investor is keeping the faith in SwanBio Therapeutics, stepping up to provide the lion’s share of a $56 million series B round that will support an early-phase clinical trial.
Philadelphia-based SwanBio is advancing a pipeline of gene therapies for spinal-cord-related disorders led by SBT101, a treatment for the genetic disorder adrenomyeloneuropathy (AMN) that is set to enter the clinic in the back half of the year. With the phase 1/2 study on the horizon, the biotech has returned to investors to top up its bank balance.
